Story
MacroGenics Shares Rise After Gilead Exercises Option, Triggering $10M Payment

Shares of MacroGenics Inc. (NASDAQ:MGNX) climbed 4.3% in after-hours trading on Tuesday after Gilead Sciences opted to exercise its license for a preclinical bispecific antibody program, triggering a $10 million payment to the company.
Details of the Agreement
The exercised option grants Gilead Sciences an exclusive license to a preclinical program targeting two undisclosed solid tumor targets. According to the announcement, the program utilizes MacroGenics’ proprietary TRIDENT platform, which is designed to create antibody-based therapeutics.
This development is part of a broader collaboration agreement established between the two companies in 2022. The partnership is focused on advancing novel cancer treatments and includes a total of three programs.
AdBroader Collaboration and Financial Outlook
Beyond the newly licensed program, the collaboration includes another preclinical bispecific program and MGD024, a clinical-stage CD123 × CD3 bispecific DART molecule. The exercise of the option signals progress within the partnership and provides MacroGenics with non-dilutive capital.
For investors, the long-term potential of the alliance remains significant. MacroGenics is eligible to receive up to approximately $1.6 billion in additional payments contingent on achieving future development, regulatory, and commercial milestones. The company is also entitled to receive royalties on worldwide net sales of any products that result from the collaboration.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.